Skip to main content

Advertisement

SpringerLink
Log in

Neurologic Complications and Considerations in HIV-Infected Persons

  • HIV/AIDS (R MacArthur, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Neurologic complications for HIV-infected persons retain significant prevalence despite an increasingly global use of antiretroviral therapies. Such complications are often ascribed to advanced immunosuppression; however, the most common neurologic problems for HIV-infected persons, distal sensory polyneuropathy and HIV-associated neurocognitive disorders, affect a significant proportion of patients who have successfully achieved immunologic restoration with normal or near-normal CD4 count levels and undetectable HIV RNA in the periphery. Understanding specific considerations for HIV-associated complications, including the epidemiology, risk factors, medication-adverse effects, and benefits of appropriate management, is vital for all providers caring for those with HIV. This review will describe such considerations, as well as providing a more detailed review of the most common neurologic complications of HIV infection, and will highlight some of the challenges involved with diagnosis, management, and long-term effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Peluso R, Haase A, Stowring L, et al. A Trojan horse mechanism for the spread of visna virus in monocytes. Virology. 1985;14:231–6.

    Article  Google Scholar 

  2. Yoshioka M, Bradley M, Shapshak P, et al. Role of immune activation and cytokine expression in HIV-1-associated neurologic diseases. Adv Neuroimmunol. 1995;5:335–58.

    Article  PubMed  CAS  Google Scholar 

  3. Gonzalez-Scarano F, Martin-Garcia J. The Neuropathogensis of AIDS. Nat Rev Immunol. 2005;19:69–81.

    Article  Google Scholar 

  4. Martin A. HIV, cognition, and the basal ganglia. In: Grant I, Martin A, editors. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994. p. 234–59.

    Google Scholar 

  5. Ances BM, Ortega M, Vaida F, et al. Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr. 2012;59:469–77.

    Article  PubMed  Google Scholar 

  6. Vivithanaporn P, Heo G, Gamble J, et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a population based study. Neurology. 2010;75:1150–8.

    Article  PubMed  CAS  Google Scholar 

  7. Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206:275–82.

    Article  PubMed  CAS  Google Scholar 

  8. Peterson J, Lee E, Hecht F, et al.: Changes in neurocognitive performance from early HIV-1 infection to initiation of ART [Abstract 80]. Presented at the 19th Annual Conference on Retroviruses and Opportunistic Infections. Seattle, WA; March 5–8, 2012.

  9. Lee E, Gisslen M, Cinque P, et al.: Early follow up of undetectable cerebrospinal fluid HIV-1 RNA during primary infection in the absence of ART [Abstract 457]. Presented at the 19th Annual Conference on Retroviruses and Opportunistic Infections. Seattle, WA; March 5–8, 2012.

  10. •• Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–99. These consensus guidelines for diagnosing forms of HAND not only are important for researchers, but also are valuable for clinicians, especially with the understanding of how the different forms vary by level of testing performance and level of daily impairments. Additionally, the article includes descriptions of how cognitive impairments in HIV-infected persons have changed over the years, and it is important to clinically recognize the often subtler symptoms that are prevalent now.

    Article  PubMed  CAS  Google Scholar 

  11. •• Heaton RK, Clifford DB, Franklin DR JR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75:2087–96. This large multicenter cohort study with strong methodology highlights the overwhelming prevalence of HAND in the HIV population.

    Article  PubMed  Google Scholar 

  12. •• Gorman AA, Foley JM, Ettenhofer ML, et al. Functional consequences of HIV-associated neurocognitive impairment. Neuropsychol Rev. 2009;19:186–203. This extensive and well-organized review of outcomes for patients affected with HAND emphasizes the role that even subtle disease can have major impacts on activities of daily living.

    Article  PubMed  Google Scholar 

  13. Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:273–8.

    Article  PubMed  CAS  Google Scholar 

  14. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005;19:1367–74.

    PubMed  Google Scholar 

  15. Skinner S, Adewale AJ, DeBlock L, et al. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med. 2009;10:246–52.

    Article  PubMed  CAS  Google Scholar 

  16. Wright EJ, Grund B, Robertson K, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology. 2010;75:864–73.

    Article  PubMed  CAS  Google Scholar 

  17. Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS. 2011;25:357–65.

    Article  PubMed  Google Scholar 

  18. Marra CM, Lockhart D, Zunt JR, et al. Changes in CSF and plasma HIV-1and cognition after starting potent antiretroviral therapy. Neurology. 2003;60:1388–90.

    Article  PubMed  CAS  Google Scholar 

  19. Moore DJ, Roediger M, Eberly L. Clinical Evaluation of Neurocognitive and Neuropsychiatric Dysfunction [Abstract 499]. Presented at the 19th Annual Conference on Retroviruses and Opportunistic Infections. Seattle, WA; March 5–8, 2012.

  20. Koski L, Brouillette MJ, Lalonde R, et al. Computerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment. HIV Med. 2011;12:472–80.

    Article  PubMed  CAS  Google Scholar 

  21. • Cysique LA, Murray JM, Dunbar M, et al. A screening algorithm for HIV-associated neurocognitive disorders. HIV Med. 2010;11:642–9. This study describes a quick bedside questionnaire for screening patients for HAND with good sensitivity and specificity.

    Article  PubMed  CAS  Google Scholar 

  22. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25:1747–51.

    Article  PubMed  CAS  Google Scholar 

  23. Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005;11:265–73.

    Article  PubMed  Google Scholar 

  24. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007;45:174–82.

    Article  PubMed  Google Scholar 

  25. Cole MA, Margolick JB, Cox C, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology. 2007;69:2213–20.

    Article  PubMed  CAS  Google Scholar 

  26. Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology. 2011;77:1135–42.

    Article  PubMed  CAS  Google Scholar 

  27. Zhao Y, Navia BA, Marra CM, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials. 2010;11:59–67.

    Article  PubMed  CAS  Google Scholar 

  28. Evans SR, Yeh TM, Sacktor N, et al. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials. 2007;8:437–46.

    Article  PubMed  Google Scholar 

  29. Iudicello JE, Kellogg EJ, Weber E, et al. Semantic cueing improves category verbal fluency in persons living with HIV infection. J Neuropsychiatry Clin Neurosci. 2012;24:183–90.

    PubMed  Google Scholar 

  30. Weber E, Woods SP, Kellogg E, Grant I, Basso MR. Self-generation enhances verbal recall in individuals infected with HIV. J Int Neuropsychol Soc. 2012;18:128–33.

    Article  PubMed  Google Scholar 

  31. Cusini A, Vernazza PL, Yerly S, et al.: Higher CNS Penetration-Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr. 2013;62:28–35.

    Google Scholar 

  32. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359–66.

    Article  PubMed  Google Scholar 

  33. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73:1292–9.

    Article  PubMed  CAS  Google Scholar 

  34. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012;78:485–92.

    Article  PubMed  CAS  Google Scholar 

  35. Achim CL, Adame A, Dumaop W, et al. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol. 2009;4:190–9.

    Article  PubMed  Google Scholar 

  36. Green DA, Masliah E, Vinters HV, et al. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS. 2005;19:407–11.

    Article  PubMed  CAS  Google Scholar 

  37. • Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS. 2005;19:127–35. The authors report on how the HIV-1 protein inhibits amyloid clearance but also describe how this inhibition actually leads to CNS amyloid deposition. The discussion concisely summarizes the clinical implications of amyloid deposition in HIV-infected patients.

    Article  PubMed  CAS  Google Scholar 

  38. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry. 1998;65:29–33.

    Article  PubMed  CAS  Google Scholar 

  39. •• Ellis RJ, Rosario D, Clifford DB, et al. ontinued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010;67:552–8. The authors report on HIV-SN within a large cohort of HIV-positive patients and describe very high prevalence despite the use of CART and the numerous risk factors that are associated with HIV-SN.

    Article  PubMed  Google Scholar 

  40. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 1999;52:607–13.

    Article  PubMed  CAS  Google Scholar 

  41. Tagliati M, Grinnell J, Godbold J, et al. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol. 1999;56:84–9.

    Article  PubMed  CAS  Google Scholar 

  42. Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol. 2004;61:546–51.

    Article  PubMed  Google Scholar 

  43. Schifitto G, McDermott MP, McArthur JC, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology. 2002;58:1764–8.

    Article  PubMed  CAS  Google Scholar 

  44. Fellows RP, Byrd DA, Elliott K, et al. Distal sensory polyneuropathy is associated with neuropsychological test performance among persons with HIV. J Int Neuropsychol Soc. 2012;18:898–907.

    Article  PubMed  Google Scholar 

  45. Zhou L, Kitch DW, Evans SR, et al. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy. Neurology. 2007;68:2113–9.

    Article  PubMed  CAS  Google Scholar 

  46. Keswani SC, Jack C, Zhou C, et al. Establishment of a rodent model of HIV-associated sensory neuropathy. J Neurosci. 2006;26:10299–304.

    Article  PubMed  CAS  Google Scholar 

  47. Wallace VC, Blackbeard J, Segerdahl AR, et al. Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain. 2007;130:2688–702.

    Article  PubMed  Google Scholar 

  48. Brittain JM, Duarte DB, Wilson SM, et al. Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca(2)(+) channel complex. Nat Med. 2011;17:822–9.

    Article  PubMed  CAS  Google Scholar 

  49. Ripsch MS, Ballard CJ, Khanna M, et al. A peptide uncoupling CRMP-2 from the presynaptic CA(2+) channel complex demonstrates efficacy in animal models of migraine and AIDS therapy-induced neuropathy. Transl Neurosci. 2012;3:1–8.

    Article  PubMed  Google Scholar 

  50. • Phillips TJ, Cherry CL, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5:e14433. The meta-analysis section of this paper describes the few published clinical trials of medications that are commonly prescribed for HIV-associated painful neuropathies.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Neurology, Johns Hopkins University School of Medicine, 600 North Wolfe St, Meyer 6113, Baltimore, MD, 21287, USA

    Justin McArthur & Bryan Smith

Authors
  1. Justin McArthur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bryan Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Justin McArthur.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McArthur, J., Smith, B. Neurologic Complications and Considerations in HIV-Infected Persons. Curr Infect Dis Rep 15, 61–66 (2013). https://doi.org/10.1007/s11908-012-0312-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-012-0312-2

Keywords

Search

Navigation